Johnson and Johnson sees medical device sales growth in Q3 2010

Johnson and Johnson has published its financial report for the third quarter of 2010, reporting satisfaction with its "solid earnings" for the three-month period.

The healthcare group's global sales for the quarter totalled $15 billion (9.5 billion pounds), with its medical device and diagnostics unit contributing the largest share at $5.9 billion.

Johnson and Johnson noted that sales in this division were up by 1.3 percent compared to Q3 2009, thanks to strong sales of Ethicon's surgical care range, Ethicon Endo-Surgery's advanced sterilisation products and DePuy's orthopaedic joint reconstruction business.

The firm was also able to expand the business unit via the acquisition of Micrus Endovascular, a deal valued at $480 million that was completed last month.

William Weldon, chairman and chief executive officer of Johnson and Johnson, said of the group as a whole: "We continue to deliver solid earnings while investing in our future through complementary strategic partnerships and acquisitions."